A beginner’s guide to stock valuation

Published 05-AUG-2020 16:35 P.M.

|

5 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

How do you work out which stocks represent sensible long-term investments? Navexa's Navarre Trousselot dives into the world of valuing potential investments on the stock market.

With more than 2,200 listings on the ASX, how do you choose a single stock to invest in?

For many of us — especially those of us who hunt for value over the long term — the process begins with valuing a company whose shares trade on the stock market.

It won’t come as a surprise that there are many ways to go about valuing a company.

We all approach investing and building wealth in our own way.

Just as some investors look for high potential growth stocks that could explode hundreds of percent higher in a short time...

And others prefer to buy and hold large, relatively stable stocks for a long time...

There’s a variety of options available to you as you evaluate the value of a potential investment.

Here, we explain a few of the main ones.

First, though ...

What does it mean to value a stock — and why should you do it?

When you buy shares, you own a fraction of the company whose stock you acquire.

This means that before you buy shares in it, it makes sense that you understand the business you’re buying into.

This, in turn, means you need to delve into the business’s finances.

The phrase ‘due diligence’ refers to this process.

If you don’t know what you’re buying into, then you’re not investing.

You’re gambling.

Your due diligence — the necessary research, in other words — is what differentiates a bet from an investment (which is still a risk, of course, but a calculated one).

Determining a business’s financial health allows you to understand whether or not its share price accurately reflects the company’s value.

The stock market is seldom a perfect reflection of the value of the companies trading shares on it.

After all, everyone in the market is looking for opportunities to make money by speculating on the future.

This means that a company’s shares can easily trade below or above the ‘true’ value of the business they represent.

This is where valuing a stock gets interesting.

Popular ways of valuing a stock

The simplest measure investors use when trying to get a handle on a stock’s value is the price to earnings ratio, or P/E ratio.

The P/E ratio is the current share price divided by what the company earned for every share over the past year.

Generally speaking, the higher the P/E ratio, the more overvalued you might say a company’s shares are.

A lower P/E, on the other hand, might indicate the market undervalues the shares relative to the overall health of the business.

Other common ways to approach valuation include:

Cash flow: While a stock might not be getting much love from investors and trading cheap, you might fight when you dig into their financials that the business has a strong cash flow (that they make a good return on their spending, in other words). This could be an indicator that the share price will rise higher as the market notices the business making more money in the future.

Debt ratio: Work out how much money the businesses owes to others. Low debt, generally speaking, is a positive sign that a company is healthy and its stock price may rise in the future.

Assets/liabilities: Another helpful ratio to deploy in valuation research is assets/liabilities. This is exactly what is sounds like. Divide the value of the company’s assets by the value of its liabilities. The higher the ratio, the better.

Using Navexa’s Built-In Value Calculator

There are, as they say, many ways to skin a cat.

When it comes to valuing a stock, there’s a huge array of ratios, calculations and methods available to help you get an idea of where a company’s shares are trading relative to its ‘true’ value.

It’s up to you to find the method that best fits your investing style and wealth building goals.

But to make life a little easier for our users when they are trying to value a stock, we’ve built a simple value calculator into our portfolio tracker.

Our calculator uses the discounted cash flow method.

This method determines the value of an investment based on future cash flow.

It’s based partly on hard, current numbers, and partly on predicted or forecast future numbers.

This method is similar to what Warren Buffett uses to value a stock.

If the discounted cash flow works out to be higher than the current cost of the investment, this is an indication that the price could rise in the future.

It’s not guaranteed or 100% accurate. No method that estimates future events can be.

And it is just one of the ways to go about determining value when evaluating a stock.

We recommend you try different methods until you find one that suits you best.

Navarre is the Founder of Navexa — a portfolio analytics service made for Australian investors. Navarre left a lucrative corporate developer job to combine two of his passions; investing and entrepreneurship. He created Navexa because he couldn’t find a portfolio analytics service that met his own high standards. Now, he’s focused on helping as many Australians as possible get more from their portfolios through the smart and creative use of data. Follow Navarre on Twitter and connect with him on LinkedIn.

This article was originally published on https://www.navexa.com.au/blog/a-beginners-guide-to-stock-valuation



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X